Hot topics close

Dexus offloads North Sydney office block for $95m to meet redemptions

Dexus offloads North Sydney office block for 95m to meet redemptions
Sources say 124 Walker Street was sold at a discount to its June 2023 valuation of A$120m

The Dexus Wholesale Australian Property Fund (DWAPF) has sold an older office block in North Sydney to a Singapore investor for A$95m (€57m) to help meet redemption requests.

Dexus which inherited the A$2.3bn open-ended fund when it bought the Australia funds management platform from the former AMP Capital, told investors of the fund last year that they would have to wait up to 12 months for redemption requests to be met.

The manager was implementing an asset sales programme to raise capital but the divestment was taking longer because of the difficult market conditions.

Sources said the asset was sold at a discount to its June 2023 valuation of A$120m.

The recently refurbished building at 124 Walker Street, North Sydney, which was constructed in 1974, was among a trio of smaller assets that Dexus divested for a total of around A$185m.

A Dexus spokesperson the divestment reduced the fund’s exposure to the office market, decreased the average age of the portfolio and increased the average occupancy of the portfolio.

The disposal had extended the average lease expiry profile of the fund and improved “the capital management strength of the fund”, he said. but he declined to reveal the identify of the buyer, citing commercial reasons.

To read the latest IPE Real Assets magazine click here.

News Archive
  • Hamish Gaman
    Hamish Gaman
    'Vulnerable' Hamish Gaman pulls out of tonight's Dancing One Ice and claims someone is 'trying to destroy'...
    16 Feb 2020
    2
  • Emma Stone
    Emma Stone
    Emma Stone says she would like to be called her real name
    26 Apr 2024
    20
  • Cold Call
    Cold Call
    Cold Call release schedule – How many episodes in Channel 5 ...
    17 Jun 2024
    2
  • Infliximab
    Infliximab
    New data show non-inferiority of efficacy for subcutaneous formulation of CT-P13 (biosimilar infliximab) to intravenous ...
    10 Nov 2019
    1
This week's most popular news